登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>CD5 >CD5-HF255

FITC-Labeled Human CD5 Protein, Fc Tag (MALS verified)

分子别名(Synonym)

CD5,LEU1

表达区间及表达系统(Source)

FITC-Labeled Human CD5, Fc Tag (CD5-HF255) is expressed from human 293 cells (HEK293). It contains AA Arg 25 - Pro 372 (Accession # P06127-1).

Predicted N-terminus: Arg 25

Request for sequence

蛋白结构(Molecular Characterization)

CD5 Structure

This protein carries a human IgG1 Fc tag at the C-terminus.

The protein has a calculated MW of 65.1 kDa. The protein migrates as 75-95 kDa and >116 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

偶联(Conjugate)

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 535 nm

标记(Labeling)

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>90% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

CD5 SDS-PAGE

FITC-Labeled Human CD5, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS

CD5 SEC-MALS

The purity of FITC-Labeled Human CD5, Fc Tag (Cat. No. CD5-HF255) is more than 90% and the molecular weight of this protein is around 135-165 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

CD5 ELISA

Immobilized FITC-Labeled Human CD5, Fc Tag (Cat. No. CD5-HF255) at 1 μg/mL (100 μL/well) can bind Mouse Anti-CD5 Antibody, Mouse IgG1 with a linear range of 0.2-3 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-FACS

CD5 FACS

5e5 of Anti-CD5 CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human CD5, Fc Tag (Cat. No. CD5-HF255) and negative control protein respectively. FITC signal was used to evaluate the binding activity (QC tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

T-cell surface glycoprotein CD5 is also known as Lymphocyte antigen T1/Leu-1 and LEU1,which is phosphorylated on tyrosine residues by LYN,so CD5 can create binding sites for PTPN6/SHP-1.CD5 may act as a receptor in regulating T-cell proliferation. CD5 is expressed at various developmental and activation stages on human B cells.CD5 is a well established negative regulator of TCR and BCR signalling.CD5-positive cells may also prevent the emergence of autoimmunity by provision of cytokines such as IL-10. Development,selection and function of different B- and T-cell subsets or their preferential survival may be directly or indirectly dependent on different glycan structures associated with CD5 or CD5-like molecules.

 

前沿进展

Building a new score system for the diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL based on the flow cytometry immunophenotyping
Niyonizeye, Wang, Yan et al
Ann Hematol (2025)
Abstract: The diagnosis and differential diagnosis of typical lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma(SLL) especially atypical CLL/SLL (aCLL/SLL), and mantle cell lymphoma (MCL) remains highly challenging. Thus, we evaluated the accuracy of the combination of the Moreau score system (MSS) indicators (markers), with three new indicators CD19/CD20 ratio, CD200, and CD43 in diagnosis and differential diagnosis of typical CLL/SLL, atypical CLL/SLL, and MCL. We retrospectively retrieved data from peripheral blood, bone marrow, and lymph nodes of 120 patients comprising 64 typical CLL, 10 atypical CLL, and 46 MCL from March 2020 to September 2023 at the First Affiliated Hospital of Zhengzhou University. Multiparametric evaluation flow cytometry and immunophenotype were obtained via a B-cell panel and pathological reports were carried out. We observe that the new score system (NSS) and the MSS had the same specificity. However, the NSS demonstrated to have superior sensitivity compared to MSS. Adding three new markers CD19/CD20, CD200, and CD43 is accountable for the superior sensitivity in our NSS. Also, a combination of markers such as CD19, CD20, CD5, CD23, CD79b, FMC7, SmIg, CD22, CD43, CD200, the ratio CD19/CD20 may be a potential differentiating modality for typical CLL/SLL, atypical CLL/SLL, and MCL. Adding the CD19/CD20 ratio, CD43, and CD200 indicators to the MSS indicators could be potentially accurate diagnostic and differential diagnosis modality for typical CLL/SLL, atypical CLL/SLL, and MCL.© 2025. The Author(s).
Lymphocytic Variant Hypereosinophilic Syndrome: Case Series From a Tertiary Referral Center in Canada
Wang, Shopsowitz, Lofroth et al
EJHaem (2025) 6 (2), e1109
Abstract: Lymphocytic variant hypereosinophilic syndrome (L-HES) is a rare disorder characterized by persistent eosinophilia driven by aberrant T-cell populations. Diagnosis remains challenging due to the lack of standardized diagnostic criteria.We retrospectively analyzed 18 patients diagnosed with L-HES between 2016 and 2023. Comprehensive flow cytometry was performed on peripheral blood samples.Nine patients demonstrated the classic sCD3-CD4+CD5+CD2+CD45RO+CD45RA- immunophenotype, ranging from 0.6% to 70% of total lymphocytes. Two patients showed variant sCD3-CD4+ phenotypes, five had expanded (> 10%) sCD3+CD4+CD7- T-cells, and two displayed aberrant CD8+ T-LGL populations. Clonality was established in all patients with nonclassic phenotypes by molecular TCR testing or based on uniform TRBC1. We assessed a serial gating strategy to quantify the classic L-HES phenotype and found this to be highly sensitive and specific with an estimated limit of detection of 0.06% of lymphocytes. Using this strategy, we identified decreased but detectable abnormal T-cells in all classic phenotype patients reassessed posttreatment, down to as low as 0.3% of lymphocytes. The identification of T-LGL phenotypes with eosinophilia is a novel finding.Our study highlights the diverse immunophenotypic spectrum of L-HES, emphasizing the importance of comprehensive flow cytometry analysis for accurate diagnosis.© 2025 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
[Composite diffuse large B-cell lymphoma and CD5-negative mantle cell lymphoma: report of a case]
Li, Tang, Liu et al
Zhonghua Bing Li Xue Za Zhi (2025) 54 (4), 397-399
PromarkerD Versus Standard of Care Biochemical Measures for Assessing Future Renal Function Decline in Type 2 Diabetes
Peters, Joubert, Bringans et al
Diagnostics (Basel) (2025) 15 (6)
Abstract: Background/Objectives: The current standard of care for assessing chronic kidney disease complicating diabetes (DKD) includes measurement of estimated glomerular filtration rate (eGFR) and urinary albumin:creatinine ratio (uACR) but both tests have limitations. The present study compared the biomarker-based Promarker®D test with conventional biochemical measures for predicting future kidney function decline in adults with type 2 diabetes (T2D). Methods: Baseline concentrations of apolipoprotein A-IV, CD5 antigen-like protein and insulin-like growth factor binding protein 3 were combined with age, serum HDL cholesterol and eGFR to generate PromarkerD risk scores for incident DKD/eGFR decline ≥ 30% (the primary endpoint) in 857 adults with T2D (mean age 65.4 years, 54% males). Logistic regression modelling was used to compare the association of (i) PromarkerD, (ii) eGFR, (iii) uACR, and (iv) eGFR plus uACR with this outcome during 4 years of follow-up. Results: Study participants were classified by PromarkerD as low (63%), moderate (13%), or high risk (24%) for kidney function decline at baseline. Over a mean 4.2 years, 12.5% developed the primary endpoint. PromarkerD scores showed significantly higher predictive performance (area under the receiver operating characteristic curve (AUC) 0.88 (95% confidence interval (CI) 0.85-0.91)) compared to conventional biochemical measures (AUC = 0.63-0.82). There was a progressive increase in risk with moderate and high risk by PromarkerD exhibiting greater odds of the primary endpoint compared to those at low risk (odds ratios (OR) (95% CI) 8.11 (3.99-16.94) and 21.34 (12.03-40.54), respectively, both p < 0.001). Conclusions: PromarkerD more accurately identifies adults with T2D at risk of kidney function decline than current usual care biochemical tests.
Showing 1-4 of 8060 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CD5靶点信息
英文全称:T-cell surface glycoprotein CD5
中文全称:T细胞表面糖蛋白CD5
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:8详情
最高研发阶段:临床二期
查看更多信息
前沿进展
点击查看详细
相关产品
View All CD5

消息提示

请输入您的联系方式,再点击提交!

确定